Accent Microcell Ltd IPO
Open Demat Account
Accent Microcell Ltd IPO Details
Details
Total Shares Offered | Offer to Public | Retail Max (Shares) | Pre Issue Promoters Holding | Exchange | Issue size |
---|---|---|---|---|---|
₹ 56 L | TBA | ₹ 18.62 L | ₹ 109.7 L | NSE | ₹ 78.4 Cr |
IPO Open Date | Close Date | Lot Size | Min Investment | Issue Type | Listing Date |
08 Dec, 23 | 12 Dec, 23 | 1000 | ₹ 1,33,000 | Book Building - SME | 15 Dec, 23 |
Accent Microcell Ltd IPO Dates
Details
Sector | Type |
---|---|
Sector | Pharmaceuticals - Indian - Bulk Drugs & Formln |
Sub Sector | NA |
Issue Type | Book Building - SME |
Subscription Status
*Values are in Lakhs
Investor Type | Subscription Times | Shares Offered* | Shares Bid* |
---|---|---|---|
QIB | 0x | 2660000 | 0 |
NII | 0x | 798000 | 0 |
Retail | 0x | 1862000 | 0 |
Employee | 0x | 0 | 0 |
Total | 0x | 5600000 | 0 |
Subscription Status
Investor Type
QIB
NII
Retail
Employee
Total
*Values are in Lakhs
Accent Microcell Ltd Financial Status
Income Statement
Balance Sheet
Particulars (in Rs. Crores) | FY23 | FY22 | FY21 |
---|---|---|---|
Revenue from operations | 40.96 | 18.91 | 11.74 |
EBITDA | 45.39 | 23.02 | 15.89 |
PAT | 30.17 | 12.23 | 5.89 |
Total Assets | 163.69 | 77.62 | 64.17 |
Share Capital | 21.04 | 12.94 | 12.90 |
Total Borrowings | 17.18 | 23.09 | 17.56 |
Operating Activities (Net Cash) | 34.60 | 16.34 | 10.04 |
Investing Activities (Net Cash) | -1.86 | 0.00 | 0.00 |
Financing Activities (Net Cash) | 17.18 | 23.09 | 17.56 |
Net Cashflow | 72.49 | 2.05 | 2.83 |
Particulars (in Rs. Crores)
Revenue from operations
EBITDA
PAT
Total Assets
Share Capital
Total Borrowings
Operating Activities (Net Cash)
Investing Activities (Net Cash)
Financing Activities (Net Cash)
Net Cashflow
About Accent Microcell Ltd
The Company was originally incorporated on April 10, 2012 as a Private Limited Company as Accent Microcell Private Limited vide Registration No. 069799 under the provisions of the Companies Act, 1956 with the Registrar of Companies, Gujarat, Dadra and Nagar Haveli. Subsequently, pursuant to a special resolution passed by the Shareholders at their Extraordinary General Meeting held on December 05, 2022, the Company was converted from a Private Limited Company to Public Limited Company and consequently, the name of the Company was changed to Accent Microcell Limited and a Fresh Certificate of Incorporation consequent to Conversion was issued on December 23, 2022 by the Registrar of Companies, Ahmedabad. The Corporate Identification Number of the Company is U24230GJ2012PLC069799.
Pharmaceuticals Market size was valued at USD 209.85 billion in 2021 and is poised to grow from USD 222.4 billion in 2022 to USD 352.98 billion by 2030, growing at a CAGR of 5.9% in the forecast period (2023-2030). With about 46% of the market share, North America was the largest market for pharmaceuticals in the global pharmaceuticals market in 2021. The Asia Pacific was the second largest region making up more than 26% of the global pharmaceuticals market. Although the need for medicines is much greater in Africa, it holds the smallest market share in the global pharmaceuticals market. The Indian Pharmaceutical industry is currently ranked third in pharmaceutical production by volume after evolving over time into a thriving industry growing at a CAGR of 9.43% since the past nine years. Generic drugs, over-the-counter medications, bulk drugs, vaccines, contract research & manufacturing, biosimilars, and biologics are some of the major segments of the Indian pharma industry. India has the greatest number of pharmaceutical manufacturing facilities that are in compliance with the US Food and Drug Administration (USFDA) and has 500 API producers that make for around 8% of the worldwide API market. Market size of India pharmaceuticals industry is expected to reach US$ 65 billion by 2024, and ~US$ 130 billion by 2030. According to the government data, the Indian pharmaceutical industry is worth approximately US$ 50 billion with over US$ 25 billion of the value coming from exports. About 20% of the global exports in generic drugs are met by India.
The company was incorporated on April 10, 2012, with the primary focus on manufacturing of the high-quality cellulose-based excipients which predominantly find application in the Pharmaceutical, Nutraceutical, Food, Cosmetic and other industries. - the company manufactures cellulose-based excipients as follows: - Microcrystalline Cellulose (MCC) - Spray Dryer / Spin Flash Dried. - Microcrystalline Cellulose Spheres (MCC Spheres). - Silicified Microcrystalline Cellulose (SMCC). - Powdered Cellulose (PC). - Croscarmellose Sodium (CCS). - Magnesium Stearate (Mg. St.). - Microcrystalline Cellulose with Carboxy Methyl Cellulose (Co-Processed). Presently, the company majorly manufactures Microcrystalline Cellulose (MCC). MCC is an odourless, fine white powder & a purified form of cellulose, which is derived from refinement of highly purified wood pulp. It is widely used as texturizer, anticaking agent, binder, lubricant, a bulking agent, diluent which finds a wide range of applications in Pharmaceutical, Nutraceutical, Food, Cosmetic and other industries. The company manufactures 22 grades of MCC, with particle sizes ranging from 20 microns to 180 microns. The major grades of MCC manufactured and marketed by the Company are branded under the name accel. Besides accel the company also sells its products under the name acrocell, maccel and Vincel.
Peer Comparison:
- Sigachi Industries Ltd
Accent Microcell Ltd IPO Key Points
Strengths
- Experienced Promoter and management team with strong industry expertise and successful track record.
- One of the leading manufacturers of MCC (cellulose based excipient) with over two decades experience.
- Established Global presence.
- Long term relationship with clients and repeat & diversified business.
- Versatile, Technically Sound operation Team, which understands creativity at its excellence.
Risk
- The Company is party to the case Aryavart Foundation V/S Hemani industries Ltd. & Ors for non-compliance of environmental laws.
- The company may face several risks associated with the proposed expansion of its manufacturing of CCS at the Proposed Unit, which could hamper its growth, prospects, cash flows and business and financial condition.
- There may be potential conflict of interests between the Company and its Group Entities.
Strategy
- Establishing New Facility to meet the rising demand for CCS, SSG, and CMC.
- Diverse Product Portfolio & Quality Services.
- Increasing its Global presence.
- Focus on quality.
- Experienced Promoter and management team with strong industry expertise and successful track record.
- One of the leading manufacturers of MCC (cellulose based excipient) with over two decades experience.
- Established Global presence.
- Long term relationship with clients and repeat & diversified business.
- Versatile, Technically Sound operation Team, which understands creativity at its excellence.
How To Apply for Accent Microcell Ltd IPO Online?
Step 1:
Log in to the BlinkX stock market app and click ‘IPO’ in the Xplore section.
Step 2:
From the list of open IPOs, select the IPO you want to invest.
Step 3:
Go through the IPO details like lot size, price band, about the company, etc.
Step 4:
Click ‘Apply IPO’ to apply and enter the number of lots and bidding price along with your UPI ID.
Step 5:
Confirm your bid and accept the payment mandate sent to your UPI App for completing the IPO application.